AORT vs. ATRC, EMBC, ATRI, SILK, MDXG, KIDS, FNA, SIBN, OFIX, and IRMD
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include AtriCure (ATRC), Embecta (EMBC), Atrion (ATRI), Silk Road Medical (SILK), MiMedx Group (MDXG), OrthoPediatrics (KIDS), Paragon 28 (FNA), SI-BONE (SIBN), Orthofix Medical (OFIX), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
Artivion (NYSE:AORT) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
In the previous week, AtriCure had 1 more articles in the media than Artivion. MarketBeat recorded 6 mentions for AtriCure and 5 mentions for Artivion. Artivion's average media sentiment score of 0.60 beat AtriCure's score of 0.60 indicating that Artivion is being referred to more favorably in the media.
Artivion has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
Artivion has a net margin of -2.61% compared to AtriCure's net margin of -8.98%. Artivion's return on equity of 3.64% beat AtriCure's return on equity.
AtriCure has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.
86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 8.1% of Artivion shares are owned by insiders. Comparatively, 3.2% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Artivion presently has a consensus target price of $27.50, suggesting a potential upside of 16.62%. AtriCure has a consensus target price of $49.78, suggesting a potential upside of 125.04%. Given AtriCure's higher possible upside, analysts plainly believe AtriCure is more favorable than Artivion.
AtriCure received 533 more outperform votes than Artivion when rated by MarketBeat users. However, 70.00% of users gave Artivion an outperform vote while only 68.98% of users gave AtriCure an outperform vote.
Summary
Artivion beats AtriCure on 9 of the 17 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artivion Competitors List
Related Companies and Tools
